Monte Rosa Therapeutics : Corporate Presentation – March 2025
GLUE
Proteome Editing Through Molecular Glue Degraders
Innovating Beyond New Heights | March 2025
Monte Rosa Therapeutics - Company Overview
Proteome editing with molecular glue degraders
Unique and
Industry-leading
differentiated "only in
class" portfolio
discovery engine
combining use of AI with
Arsenal of rationally
experimental platform
designed MGDs to edit
to enable rational design
the proteome by
of novel MGDs
degrading proteins with
unprecedented precision
Strong financial
position providing cash
runway into 2028
through multiple
anticipated proof-of-
concept clinical readouts
3
Our Molecular Glue Degraders (MGDs) Edit the Proteome
Ubiquitin chain
Neosubstrate
(target protein)
Neosubstrate
MGDUbiquitination
MGD
Ligase
Ligase
Ternary
Neosubstrate
complex
Proteasome-mediated
degradation of neosubstrate
4
Monte Rosa's rationally designed MGDs have potential applications in oncology,
immunology, neuroscience and other therapeutic areas
Key Insights into Surface Interactions Drive Only-in-Class MGD Designs
E3 ligase
E3 ligase
neosurface
Neosubstrate footprint
MGD footprint
Interrogating surfaces using
geometric deep learning informs
reprogrammable ligase and
matching target space…
5
Key Insights into Surface Interactions Drive Only-in-Class MGD Designs
...and creates broad opportunity to eliminate undruggable, disease-driving proteins through
"only-in-class" MGDs
Grow
Target Space
(e.g., I&I, neurology)
MGDs
Activate
New E3 Ligases
CRBN
Ligases
Expand
Chemical Space
(MGD Library)
6
Three Ways to Eliminate a Disease-Causing Protein
MGDs can directly and precisely target proteins that cause disease
MGD
CRISPR gene editing
RNAi/ASO
MGD
DNA mRNA protein
7
Three Ways to Eliminate a Disease-Causing Protein
MGDs provide advantages of large molecule modalities with orally dosed small molecules
MGD
Properties
Address
undruggable space
Highly selective
Orally bioavailable
Systemic
distribution
Scalable
manufacturing
Reversible
CRISPRRNAi/ASO
✓ ✓
✓ ✓
✓
CRISPRRNAi/ASO
MGD
✓
✓
✓
✓
✓
✓
MGD
8
nucleus
DNA
mRNA
protein
Key Advantages of Our Rationally Designed MGDs
Unprecedented Selectivity
Catalytic Mechanism of Action
Target
Statistical significance (P-value; -log10)
Protein degradation (fold-change; log2)
POI-directed
CRBN MGD
+
POI
Complex
formation
POI degradation
MGD available for additional degradation
Unique insights into anatomy of protein-protein-MGD
interaction allows unprecedented MGD selectivity
Long lasting, catalytic protein degradation effect
creates differentiated target product profiles
9
POI = protein of interest
Portfolio and Partnerships
Monte Rosa Pipeline and Upcoming Milestones
Oncology Immunology & Inflammation
Various
Next
Target
Compound
Indication(s)
Discovery
IND-Enabling
Clinical
Anticipated
Ownership
Milestone
VAV1
MRT-6160
Immune-mediated
Phase 2 initiation
*
Diseases
MRT-8102
IL-1β/NLRP3-driven
IND submission
in H1 2025
NEK7
Inflammatory
IND submission
CNS Optimized Diseases
in 2026
GSPT1
MRT-2359
Castration-resistant
Additional CRPC data
Prostate Cancer
in H2 2025
CCNE1 Amplified Tumors,
CCNE1/CDK2
Discovery
IND submission
Breast Cancer
in 2026
Multiple Targets
Discovery
I&I, Genetic Diseases,
Lead optimization
Oncology
Multiple Targets
Discovery
Oncology and
Undisclosed
Neurological Diseases
11
* Monte Rosa has an exclusive global license agreement with Novartis for this asset.
Disclaimer
Monte Rosa Therapeutics Inc. published this content on March 20, 2025, and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 20, 2025 at 11:35:18.927.